Logo image of NYKD.OL

NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Fundamental Analysis

OSL:NYKD - Euronext Oslo - NO0010714785 - Common Stock - Currency: NOK

1.787  -0.11 (-5.95%)

Fundamental Rating

3

Overall NYKD gets a fundamental rating of 3 out of 10. We evaluated NYKD against 73 industry peers in the Biotechnology industry. The financial health of NYKD is average, but there are quite some concerns on its profitability. NYKD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NYKD had negative earnings in the past year.
NYKD had a negative operating cash flow in the past year.
NYKD had negative earnings in 4 of the past 5 years.
In multiple years NYKD reported negative operating cash flow during the last 5 years.
NYKD.OL Yearly Net Income VS EBIT VS OCF VS FCFNYKD.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

NYKD has a Return On Assets of -25.29%. This is comparable to the rest of the industry: NYKD outperforms 56.16% of its industry peers.
The Return On Equity of NYKD (-28.50%) is better than 61.64% of its industry peers.
Industry RankSector Rank
ROA -25.29%
ROE -28.5%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NYKD.OL Yearly ROA, ROE, ROICNYKD.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

NYKD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NYKD.OL Yearly Profit, Operating, Gross MarginsNYKD.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

5

2. Health

2.1 Basic Checks

NYKD does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for NYKD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NYKD.OL Yearly Shares OutstandingNYKD.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M
NYKD.OL Yearly Total Debt VS Total AssetsNYKD.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

NYKD has an Altman-Z score of 2.07. This is not the best score and indicates that NYKD is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.07, NYKD is doing good in the industry, outperforming 67.12% of the companies in the same industry.
NYKD has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
NYKD has a Debt to Equity ratio of 0.02. This is in the better half of the industry: NYKD outperforms 78.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 2.07
ROIC/WACCN/A
WACC8.36%
NYKD.OL Yearly LT Debt VS Equity VS FCFNYKD.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 12.87 indicates that NYKD has no problem at all paying its short term obligations.
With an excellent Current ratio value of 12.87, NYKD belongs to the best of the industry, outperforming 97.26% of the companies in the same industry.
A Quick Ratio of 12.87 indicates that NYKD has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 12.87, NYKD belongs to the top of the industry, outperforming 97.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.87
Quick Ratio 12.87
NYKD.OL Yearly Current Assets VS Current LiabilitesNYKD.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

NYKD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.47%, which is quite impressive.
Looking at the last year, NYKD shows a very negative growth in Revenue. The Revenue has decreased by -32.72% in the last year.
Measured over the past years, NYKD shows a very negative growth in Revenue. The Revenue has been decreasing by -36.54% on average per year.
EPS 1Y (TTM)90.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.74%
Revenue 1Y (TTM)-32.72%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-70.9%

3.2 Future

NYKD is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -66.63% yearly.
NYKD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 184.95% yearly.
EPS Next Y17.8%
EPS Next 2Y14.88%
EPS Next 3Y4.76%
EPS Next 5Y-66.63%
Revenue Next Year22.17%
Revenue Next 2Y-32.73%
Revenue Next 3Y-25.99%
Revenue Next 5Y184.95%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NYKD.OL Yearly Revenue VS EstimatesNYKD.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 2031 1B 2B 3B 4B 5B
NYKD.OL Yearly EPS VS EstimatesNYKD.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NYKD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NYKD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYKD.OL Price Earnings VS Forward Price EarningsNYKD.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYKD.OL Per share dataNYKD.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.88%
EPS Next 3Y4.76%

More info and screens

6

5. Dividend

5.1 Amount

NYKD has a Yearly Dividend Yield of 36.71%, which is a nice return.
The stock price of NYKD dropped by -30.23% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
NYKD's Dividend Yield is rather good when compared to the industry average which is at 7.88. NYKD pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, NYKD pays a better dividend.
Industry RankSector Rank
Dividend Yield 36.71%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DPN/A
EPS Next 2Y14.88%
EPS Next 3Y4.76%
NYKD.OL Yearly Income VS Free CF VS DividendNYKD.OL Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

More info and screens

NYKODE THERAPEUTICS ASA

OSL:NYKD (5/30/2025, 7:00:00 PM)

1.787

-0.11 (-5.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14
Earnings (Next)08-20 2025-08-20
Inst Owners17.19%
Inst Owner ChangeN/A
Ins Owners2.42%
Ins Owner ChangeN/A
Market Cap583.54M
Analysts80
Price Target5.44 (204.42%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 36.71%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.38%
Min EPS beat(2)32.12%
Max EPS beat(2)34.64%
EPS beat(4)4
Avg EPS beat(4)34.37%
Min EPS beat(4)2.04%
Max EPS beat(4)68.68%
EPS beat(8)8
Avg EPS beat(8)38.15%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2387.3%
Min Revenue beat(2)72.62%
Max Revenue beat(2)4701.98%
Revenue beat(4)3
Avg Revenue beat(4)1191.24%
Min Revenue beat(4)-87.77%
Max Revenue beat(4)4701.98%
Revenue beat(8)7
Avg Revenue beat(8)1878.76%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-40.74%
PT rev (3m)-57.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)12.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)13.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.6
P/FCF N/A
P/OCF N/A
P/B 0.42
P/tB 0.42
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS0.27
BVpS4.25
TBVpS4.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.29%
ROE -28.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.15%
Cap/Sales 0.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.87
Quick Ratio 12.87
Altman-Z 2.07
F-Score2
WACC8.36%
ROIC/WACCN/A
Cap/Depr(3y)80.08%
Cap/Depr(5y)78.32%
Cap/Sales(3y)17.63%
Cap/Sales(5y)11.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.74%
EPS Next Y17.8%
EPS Next 2Y14.88%
EPS Next 3Y4.76%
EPS Next 5Y-66.63%
Revenue 1Y (TTM)-32.72%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-70.9%
Revenue Next Year22.17%
Revenue Next 2Y-32.73%
Revenue Next 3Y-25.99%
Revenue Next 5Y184.95%
EBIT growth 1Y16.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.93%
EBIT Next 3Y14.26%
EBIT Next 5Y-60.17%
FCF growth 1Y47.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.99%
OCF growth 3YN/A
OCF growth 5YN/A